double-blinded trial to study whether the use of tranexamic acid in hip fracture surgery reduces the requirement for erythrocyte transfusion and whether it might reduce the risk of postoperative bacterial infection. As there remains a concern that this antifibrinolytic agent may promote a hypercoagulable state, 6 we studied its safety on venous and arterial outcomes. An updated meta-analysis combining this study with previous trials was carried out to assess the efficacy of tranexamic acid in orthopaedic surgery.
Methods
This single centre double-blinded randomized study was performed in accordance with the provisions of the Declaration of Helsinki. The protocol was approved by the local Institutional Review Board. Written informed consent was obtained from all patients or their relatives before randomization.
Consecutive patients undergoing hip fracture surgery within 48 h after trauma were included. Exclusion criteria were pregnancy or breast-feeding, contraindication for tranexamic acid ( previous arterial or venous thrombosis, creatinine clearance ,30 ml min 21 , previous seizure or oestroprogestative therapy), multiple fractures, contraindication for prophylaxis with fondaparinux (Arixtra, GlaxoSmithKline, Brentford, UK), and requirement for anticoagulant therapy that could not be stopped.
Patients were randomly allocated to a study group by permuted blocks of randomly mixed sizes and stratification according to type of surgery (arthroplasty or osteosynthesis) by means of a central telephone system with a computer-generated randomization list. In a doubleblinded fashion, patients were assigned to receive either two doses of 15 mg kg 21 of i.v. tranexamic acid (Exacyl 0.1 g ml 21 , Sanofi-Aventis, France) or two doses of i.v. placebo. The endovenous solutions were prepared outside the orthopaedic department by a nurse and directly sent to the anaesthesiologist in-charge in the operating room. Masking was ensured by the administration of apparently identical saline drips. The first dose was given just before surgery and the second 3 h later. Patient caregivers, investigators collecting the data, safety monitoring board, and members of the adjudication committee remained unaware of study-groups assignments.
Venous thromboprophylaxis included 2.5 mg of fondaparinux o.d., initiated 8 h after wound closure and continued for 35 days. All patients had general anaesthesia and a fascia iliaca compartment blockade. Drugs used for anaesthesia and postoperative analgesia were left to the discretion of the anaesthetists. However, use of non-steroidal anti-inflammatory drugs or aspirin for analgesia, aprotinin, desmopressin, recombinant factor VIIa, antithrombin or cell-savage device were prescribed. Before surgery, patients received cefazolin (2 g).
Surgical technique varied according to the type of fracture and local practice. Before surgery, a haemoglobin transfusion trigger point was determined for each patient in accordance with the French guidelines for erythrocyte blood transfusion. The transfusion trigger was 10 g dl 21 for patients at risk (acute coronary syndrome, severe left ventricular dysfunction, or chronic respiratory failure), if hypotension could not be corrected despite adequate volume replacement during surgery and in case of syncope, transient ischaemic attack, stroke, acute respiratory failure, or acute coronary syndrome after surgery. In all other cases transfusion trigger was 9 g dl 21 . During surgery, blood losses were replaced with Ringer's lactate in a 3:1 ratio, with 6% hydroxyethyl starch 130/0.4 (Voluven, Fresenius Kabi, Bad Homburg, Germany) in a 1:1 ratio, or both until haemoglobin concentration fell bellow the transfusion trigger point. Thereafter, patients received 1 U of allogeneic packed red cell at a time until haemoglobin concentration raised above the transfusion trigger. Postoperative fluid therapy was standardized for the first 12 h. Each patient received 15 ml kg 21 of rehydration fluid (Na 40 mmol l
21
, K 20 mmol l
, glucose 250 mmol l
).
HemoCue Hb 201
þ (HemoCue AB, Ä ngelholm, Sweden) was used to measure haemoglobin concentration on the day of surgery. Samples were drawn before starting anaesthesia, at least every hour during surgery, in the postanaesthetic care unit and after each transfusion of RBC. Haemoglobin was also measured on days 2, 4, 6 and 8 and after each postoperative transfusion. Cardiac troponin I concentrations were measured in the post-anaesthetic care unit on days 2 and 3 using a commercially available kit (Centaur, Bayer Diagnostics, Puteaux, France). The upper reference limit was 0.10 mg l
21
, corresponding to the 99th percentile of a reference control. 8 However, the troponin threshold used for myocardial infarction based on concentrations corresponding to a coefficient of variation equal to 10% was 0.33 mg l 21 . 9 An ECG was obtained at the time of each troponin sampling. Patients were examined daily until day 8 and at discharge. Patients underwent complete compression ultrasound examination (Philips HD11 XE, high-frequency linear probe 8.5 MHz, Best, the Netherlands) of both inferior limbs between days 7 and 10 or earlier if there was any clinical suspicion of deep venous thrombosis (DVT). At 6 weeks, investigators contacted by telephone the practitioners who had managed the patient or the patient directly. They were asked if any RBC transfusion, venous or arterial thrombosis, bacterial infection, re-operation, or death had occurred since discharge. At 1 yr death, if any, was ascertained by reviewing medical records, death registry of the town hall, or by contacting the patient's general practitioner or the patient directly.
All the outcomes were assessed by the independent adjudication committee. The primary efficacy outcome was the incidence of patients requiring the transfusion of at least 1 U of allogeneic RBC from surgery up to day 8. The secondary efficacy outcome was postoperative bacterial infection, which was defined as the composite of pneumonia, other lower respiratory tract infection, blood stream infection, urinary tract infection, superficial wound infection, deep wound infection, and osteomyelitis or septic arthritis up to 6 weeks. 10 Other efficacy outcomes included calculated blood loss based on haemoglobin balance with the assumption that blood volume on day 8 was the same as that on admission, 11 the number of RBC units transfused per patient requiring allogeneic transfusion, and the incidence of postoperative major bleeding. 3 The main safety outcome was the incidence of vascular events and death up to 6 weeks. Vascular events were defined as the composite of any DVT (confirmed symptomatic DVT and asymptomatic DVT detected by mandatory ultrasound examination), pulmonary embolism (confirmed by spiral computed tomography), stroke (confirmed by computed tomographic scan or magnetic resonance imaging), transient ischaemic attack, limb ischaemia, and acute coronary syndrome. 9 The other safety outcome was the incidence of death up to 1 yr.
All the analyses were based on the intention-to-treat principle and were conducted according to a pre-specified statistical analysis plan. The trial was designed to demonstrate whether tranexamic acid was superior to placebo in preventing allogeneic RBC transfusion. Assuming an incidence of transfusion of 50% by day 8 in the placebo group 3 and a 50% relative risk reduction, predicted from previous tranexamic acid trials in primary hip arthroplasty, 7 55 patients per treatment group were needed to provide the study with a power of 80% at a two-sided type I error of 5%. The analysis of the primary efficacy outcome was performed using a two-sided Fisher's exact test. The effect of risk factors for RBC transfusion on the primary study outcome was evaluated by multivariable logistic regression analysis. Covariates for logistic regression analysis were selected on the basis of their clinical and biological plausibility. They were first analysed for univariate influence on RBC transfusion. Only variables with a P-value less than 0.25 were included in the multivariable analysis. Treatment effect of tranexamic acid was adjusted for those risk factors that were identified at multivariate analysis. For the secondary efficacy and for the primary safety outcome, the cumulative risk of events was estimated using the Kaplan-Meier procedure and compared with the log-rank test. The KolmogorovSmirnov test was used to examine the normality of distribution of continuous variables. Odds ratio (OR), hazard ratio (HR), or number needed to treat (NNT) are presented with 95% confidence intervals. 12 Data were analysed using x 2 test or Fisher's exact test and Student's t-test or MannWhitney U-test when appropriate. A two-tailed P-value of less than 0.05 was considered to indicate statistical significance. All the analyses were performed using SAS software (SAS Institute, Cary, NC, USA). Two safety interim analyses were presented to the safety monitoring board after inclusion of 55 and 75 patients. The study was not interrupted for negative trends along prespecified safety parameters. This trial is registered at ClinicalTrials.gov (number NCT00327106).
An updated meta-analysis combining this study with previous randomized trials in orthopaedic surgery in adults was carried out. The methodology was the same as previously described. 7 Trials selected had to compare i.v. tranexamic acid with no treatment or placebo and had to be performed in hip arthroplasty, knee arthroplasty, or hip fracture surgery.
The efficacy endpoint was the proportion of patients receiving at least 1 U of allogeneic RBC transfusion according to a transfusion protocol. The meta-analysis was performed using a fixed effect model of the logarithm of the OR. The results are presented with 95% confidence intervals. The meta-analysis was performed using the software Comprehensive Meta Analysis # (Biostat, Englewood, NJ, USA).
Results
Between April 2005 and November 2006, 245 patients were screened for participation in the study, 57 patients were randomized to tranexamic acid and 53 to placebo (Fig. 1) . Patient characteristics and surgical characteristics were similar between the two groups ( Table 1) .
The primary outcome, transfusion of at least 1 U of erythrocyte blood cell occurred in 24 patients (42.1%) in the tranexamic group and in 32 (60.4%) in the placebo group (P¼0.057; Table 2 ). This was a statistical nonsignificant relative risk reduction of 30% (95% confidence interval, 21 to 52%; P¼0.055). Compared with placebo, the NNT to prevent erythrocyte transfusion was 5 with tranexamic acid (95% confidence interval, number needed to harm 1000 to 1 to NNT 3). None of the patients were transfused between admission and surgery. Rates of transfusion were similar between the two groups on the day of surgery, however rates were lower the subsequent days in the tranexamic group (Table 2) . Before surgery, the indication for erythrocyte transfusion was set at 9 g dl 21 in all the patients. The transfusion trigger was increased to 10 g dl 21 in two patients (one patient in the placebo group presented a severe hypotension during surgery and one patient in the tranexamic group presented an acute coronary syndrome in the recovery room). All transfused patients had a haemoglobin concentration below the transfusion trigger and all patients with a haemoglobin concentration inferior to the transfusion trigger were transfused, except one patient in the tranexamic group who was discharged on day 8 with a haemoglobin value of 8.8 g dl 21 . No patients received transfusion with other blood components, such as platelets or plasma.
Logistic regression analysis showed that preoperative haemoglobin value, age, and type of surgery were risk factors for erythrocyte transfusion independent of treatment group (Table 3) . The relative odds reduction after adjustment for these covariates was 70% (P¼0.03) in favour of tranexamic acid. The c-statistic for the logistic regression model was 0.90, indicating an excellent discriminating value between patients with and without erythrocyte transfusion. Table 4 shows the risk of erythrocyte transfusion estimated for patients presenting a combination of the prognostic factors.
There was no statistically significant difference between groups for the other bleeding criteria ( Table 2) .
The rate of postoperative bacterial infection at 6 weeks was 25% in the tranexamic acid group, when compared with 38% in the placebo group (HR 0.58; P¼0.12; Table 5 ).
At 6 weeks, vascular events or death occurred in nine patients in the tranexamic group and three patients in the placebo group (Table 5 ). The HR for this primary safety outcome in the tranexamic group was 2.96 (P¼0.10). There were no symptomatic venous thrombosis or ST-elevation myocardial infarction events. One patient randomized in the tranexamic group died on day 3 of multiple organ failure after surgery for intestinal obstruction and presented clinical signs of stroke before dying. Cardiac troponin I elevation above 0.10 mg l 21 occurred in eight patients (14%) in the tranexamic group and in six patients (11%) in the placebo group. At 1 yr, seven patients died in the tranexamic group and three in the placebo group (HR 2.30; 95% confidence interval, 0.59-8.87; P¼0.23).
Seven trials were added to a previous meta-analysis on the use of tranexamic acid to reduce allogeneic erythrocyte transfusion. 7 Four trials involved knee arthroplasty, 13 -16 one hip arthroplasty, 17 and two hip fracture surgery, including the present trial. 18 Lack of a transfusion protocol was the reason for excluding one study. 19 Tranexamic acid led to a significant reduction in the proportion of patients requiring allogeneic RBC transfusion in hip fracture surgery: the OR was 0.47 (P¼0.01; Fig. 2 ). Although the results for tranexamic acid were not qualitatively influenced by the type of surgery, in quantitative terms, the results support a higher efficacy in knee arthroplasty (OR 0.13; P,0.01) and in hip arthroplasty (OR 0.28; P,0.01) compared with hip fracture surgery (heterogeneity tests between subgroups P,0.01).
Discussion
In patients undergoing hip fracture surgery, administration of tranexamic acid produced a 30% relative risk reduction in the incidence of erythrocyte transfusion compared with placebo. The number needed to prevent erythrocyte transfusion was 5 in favour of tranexamic acid. The observed efficacy was mostly owing to a reduction in postoperative blood loss and resulted in fewer postoperative transfusions (Table 2) . Although results of this trial are consistent with the previously reported results in elective hip arthroplasty surgery, 7 the reduction in bleeding events in favour of tranexamic acid was not statistically significant.
The lower efficacy observed in this study as that expected, a 50% relative risk reduction, needs several comments. First, tranexamic acid was started just before surgery. Therefore, it could not interfere with preoperative blood loss that accounted for approximately one-third of total blood loss ( more efficacious when started before the initiation of hyperfibrinolysis than after. 20 -22 Whether starting tranexamic acid at admission of a hip fracture rather than on the day of surgery needs further assessment. Second, the majority of the patients were anaemic before surgery, a condition that was not observed in trials in elective arthroplasty. Third, the population of patients undergoing hip fracture surgery was quite heterogeneous in terms of the risk of blood loss. Logistic regression analysis showed that low preoperative haemoglobin value, older age and intramedullary nail osteosynthesis increased the risk of erythrocyte transfusion (Tables 3 and 4 ). These data support previous identified risk factors for increased blood loss after hip fracture surgery. 1 The odds reduction of erythrocyte transfusion after adjustment for these risk factors was 70% in favour of tranexamic acid. Fourth, a recent trial in hip fracture surgery found results similar to those observed in our study. 18 Meta-analysis of these two studies indicated that tranexamic acid significantly reduced erythrocyte transfusion (Fig. 2) . Thus, the absence of a statistically significant reduction observed in our trial is probably owing to insufficient statistical power rather than the absence of a true treatment effect of tranexamic acid.
Presumably, the major goal of reducing transfusion is the reduction of the associated risk. 23 One of the related adverse events is the transfusion-related immune modulation. 4 In hip fracture surgery, transfused patients are at higher risk of postoperative infection. 5 Thus we studied whether the use of tranexamic acid might reduce the risk of postoperative bacterial infection up to 6 weeks. Results showed a trend for a lower rate of bacterial infection with the use of tranexamic acid when compared with placebo (HR, 0.58; P¼0.12). The outcome used was a composite of the most frequent postoperative bacterial infections observed after hip fracture surgery. 5 In this study urinary tract infections accounted for most infections followed by lower respiratory tract infections ( Table 5 ). The use of this composite endpoint is questionable as the clinical importance of the components of the composite endpoint is not similar. 24 Even so each of the components is of clinical importance and related to morbidity. For example, urinary tract infections which are often considered as minor infections are linked to prolonged length of hospital stay and to increase postoperative delirium. 25 These results raise an important issue for clinical trials regarding transfusion. In 
15 (26) 10 ( the current context, studies should be planned to investigate the hypothesis that a blood sparing strategy is related to a reduction in postoperative bacterial infection. Because there remains a concern that tranexamic acid may promote a hypercoagulable state, 6 we studied its safety on venous and arterial outcomes. Results showed that there was a three-fold increased risk of vascular events with the use of tranexamic acid when compared with placebo (HR, 2.96; P¼0.10; Table 5 ). Although results were not statistically significant, they contrast with the previous findings of elective hip or knee arthroplasty, where the use of tranexamic acid did not increase the risk of venous or arterial thrombosis. 7 This discrepancy may be owing to the systematic and prospective monitoring of arterial and venous events in this trial with objective tests. Further, a composite of asymptomatic and symptomatic endpoints was used to increase the likelihood of event rates. These findings are of particular importance as a recent epidemiological study performed in hip fracture surgery indicated that cardiovascular diseases were the first cause of death as they accounted for approximately 50% of all deaths. 26 However, the clinical significance of our composite endpoint needs several comments. First, the most frequently observed adverse event was DVT. However, it only included asymptomatic DVT that were detected by mandatory ultrasound examination. During the 6 weeks follow up, no symptomatic venous thrombosis or pulmonary embolism occurred. Observed rates were low and close to those observed previously with fondaparinux in hip fracture surgery. 3 27 Second, three patients (all in the tranexamic acid group) presented an acute coronary syndrome but did not show any evidence of ST-elevation myocardial infarction and were alive at 1 yr. As there is difficulty in detecting postoperative myocardial infarction, troponin I was measured in all patients to identify myocardial damage. Recent studies in hip fracture surgery have shown that elevated troponin was frequent (27 -39%) and related to prolonged length of hospital stay, major cardiac events, and mortality. 28 29 In our study, the incidence of elevated troponin was low and similar in both groups as it occurred in eight patients (14%) in the tranexamic group and in six patients (11.3%) in the placebo group. Finally, 10 (9%) patients died within 1 yr. This rate is in the lower range of those reported in previous observational studies in which surgery was performed within 48 h after hip fracture (7 -30%). 30 Evidently, the exclusion in our study of patients with prior arterial thrombosis or patients with severe renal failure resulted in low Revisited Cardiac Risk Index scores (Table 1 ) and may have accounted for these unexpected low rates of adverse events. Thus, this trial supports the hypothesis that tranexamic acid may promote a hypercoagulable state, 6 however, the clinical significance of these findings could not be assessed.
In conclusion, this study suggests that tranexamic acid reduces the risk of erythrocyte transfusion in hip fracture surgery. However, there was a trend in an increased risk of vascular events with the use of tranexamic acid. Therefore, no definite conclusions regarding the clinical benefit-risk ratio of the use of tranexamic acid can be derived from our trial. At this time, the off-label use of this drug cannot be recommended for hip fracture surgery. Tranexamic acid in hip fracture surgery
